Chester County News and Community Website
PHILADELPHIA, PA — Passage Bio, Inc. (NASDAQ: PASG) announced that its management team will participate in the H.C. Wainwright 27th Annual Global Investment Conference, scheduled for September 8–10, 2025, in …
Passage Bio to Present at H.C. Wainwright Global Investment Conference Read More PHILADELPHIA, PA — Passage Bio, Inc. (Nasdaq: PASG) announced second-quarter 2025 results and reported key advancements in its upliFT-D clinical trial, including completion of dosing in the second cohort of …
Passage Bio Reports Strong Progress in FTD-GRN Gene Therapy Trial, Extends Cash Runway to 2027 Read More PHILADELPHIA, PA — Passage Bio, Inc. (NASDAQ: PASG) announced that its Board of Directors has approved a 1-for-20 reverse stock split, set to take effect at 12:01 a.m. Eastern time …
Passage Bio Approves 1-for-20 Reverse Stock Split to Maintain Nasdaq Compliance Read More PHILADELPHIA, PA — Passage Bio, Inc. (NASDAQ: PASG) has announced encouraging updates from the ongoing Phase 1/2 upliFT-D clinical trial for PBFT02, a one-time gene therapy for frontotemporal dementia (FTD) …
Passage Bio Reports Progress in Gene Therapy for Frontotemporal Dementia Read More PHILADELPHIA, PA — Passage Bio, Inc. (Nasdaq: PASG) has shared its financial results for the first quarter of 2025, along with updates on its ongoing clinical programs and operational advancements. …
Passage Bio Reports Q1 2025 Financial Results and Highlights Progress in Gene Therapy Development Read More PHILADELPHIA, PA — Passage Bio, Inc. (NASDAQ: PASG) announced its 2024 financial results, highlighting progress in its PBFT02 gene therapy program for frontotemporal dementia (FTD) associated with GRN mutations (FTD-GRN) …
Passage Bio Reports 2024 Financial Results and Advances in PBFT02 Program Read More PHILADELPHIA, PA — Passage Bio, Inc. (NASDAQ: PASG) has announced its participation in two upcoming investor conferences, where management will share updates on the company’s progress and engage with stakeholders.
Passage Bio to Present at Two Major Investor Conferences Read More PHILADELPHIA, PA — Passage Bio, Inc. (Nasdaq: PASG) has shared updated findings from its ongoing Phase 1/2 upliFT-D clinical trial, which evaluates PBFT02 as a potential treatment for frontotemporal dementia …
Passage Bio Reports Promising Data in Trial for Frontotemporal Dementia Treatment Read More PHILADELPHIA, PA — Passage Bio, Inc. (Nasdaq: PASG) this week reported its third quarter financial results for 2024, highlighting substantial progress in its PBFT02 gene therapy program for frontotemporal dementia …
Passage Bio Advances PBFT02 Gene Therapy Program Amidst Positive Q3 2024 Results Read More PHILADELPHIA, PA — Passage Bio, Inc. has unveiled promising interim data from its ongoing global Phase 1/2 upliFT-D clinical trial at the 14th International Conference on Frontotemporal Dementias (ISFTD2024). The study …
Passage Bio Shares Promising Data on PBFT02 for Frontotemporal Dementia Read More